Postmenopausal Osteoporosis Drugs Market Comprehensive Insight by Growth Rate, Industry Status, Forecast till 2029
Postmenopausal Osteoporosis Drugs Market is anticipated to grow at a significant CAGR during the forecast period. Postmenopausal osteoporosis is a heterogeneous disorder caused due to progressive loss of bone tissue. It can occur either after natural or surgical menopause and leads to fracture within 15 to 20 years from the cessation of ovarian function. The major factor for the growth of the market is the increasing prevalence of postmenopausal osteoporosis across the globe.
According to the Endocrine
Society, approximately 1 in 10 women over the age of 60 are affected by
osteoporosis. Additionally, one in two postmenopausal women has osteoporosis
while most women suffer a fracture during their lifetime. Hence, the increasing
prevalence of postmenopausal osteoporosis is driving the demand for
postmenopausal osteoporosis drugs which in turn is driving the growth of the
market. Furthermore, the market is growing due to ongoing R&D. For
instance, in July 2019, Sandoz (Novartis) announced the first patient enrolled
in ROSALIA. It is an integrated Phase I/III clinical study for its proposed
biosimilar denosumab. Denosumab is used for the treatment of a variety of
conditions such as osteoporosis in postmenopausal women.
Some major players in the market include Eli Lilly and Co.,
Pfizer, Inc., and Merck & Co., Inc., among others. The market players are
contributing significantly to the growth of the market by the adoption of
various strategies including mergers & acquisitions, geographical
expansion, partnerships and collaborations, and new product launches, to stay
competitive in the market. For instance, in April 2019, Amgen announced the
approval of Evenity (romosozumab-aqqg) from the US FDA. It is used for the
treatment of osteoporosis in postmenopausal women at high risk of breaking a
bone.
To Request a Sample of our Report on Postmenopausal
Osteoporosis Drugs Market:
https://www.omrglobal.com/request-sample/postmenopausal-osteoporosis-drugs-market
Market Coverage
• The market number available for – 2022-2030
• Base year- 2022
• Forecast period- 2023-2030
Segment Covered-
·
By Type
·
By Application
Regions Covered-
·
North America
·
Europe
·
Asia-Pacific
·
Rest of the World
Competitive Landscape- Eli
Lilly and Co., Pfizer, Inc., and Merck & Co., Inc., among others.
Postmenopausal Osteoporosis Drugs Market Report by
Segment
By Type
• Antiresorptive Medications
• Anabolic Medications
By Application
• Hospital
• Pharmacy
• Others
A
full Report of Postmenopausal Osteoporosis Drugs Market is Available @ https://www.omrglobal.com/industry-reports/postmenopausal-osteoporosis-drugs-market
Postmenopausal
Osteoporosis Drugs Market Report by Region
North America
·
United States
·
Canada
Europe
·
UK
·
Germany
·
Spain
·
France
·
Italy
·
Rest of Europe
Asia-Pacific
·
India
·
China
·
Japan
·
South Korea
·
Rest of APAC
Rest of the World
·
Latin America
·
Middle East & Africa
Reasons to buy from us –
1. We cover more than
15 major industries, further segmented into more than 90 sectors.
2. More than 120
countries are for analysis.
3. Over 100+ paid
data sources mined for investigation.
4. Our expert
research analysts answer all your questions before and after purchasing your
report.
About Orion Market Research
Orion Market
Research (OMR) is a market research and consulting company known for its crisp
and concise reports. The company is equipped with an experienced team of
analysts and consultants. OMR offers quality syndicated research reports,
customized research reports, consulting and other research-based services. The
company also offer Digital Marketing services through its subsidiary OMR Digital and Software development and Consulting Services
through another subsidiary Encanto Technologies.
Media
Contact:
Company
Name: Orion Market Research
Contact
Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact
no: +91 7803040404
Comments
Post a Comment